Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-12-2016 | Original Article

Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2016

Abstract

Multiple myeloma (MM) is a disease of the geriatric population with a median age at diagnosis of 69 years but most clinicians consider performance status and comorbidities rather than chronological age in determining prognosis and treatment. The purpose of this study was to assess whether and which comorbidity indices predict survival in a real life population of MM. We calculated Charlson Comorbidity Index (CCI), age combined Charlson index (CCI-age), Hematopoietic cell transplantation-specific comorbidity index (HCT-SCI) and Freiburger comorbidity index (FCI) retrospectively for 66 MM patients and compared their impact on treatment responses and overall survival (OS). Treatment response was significantly worse in groups with high CCI, CCI-age, HCT-SCI scales (p < 0.05), but FCI’s effect on treatment response was not significant. However, while no significant relationship was determined between other comorbidity indices with OS, it was related only with FCI–CI (p = 0.006). FCI, developed in this patient group, was the only prognostic index with a significant effect on OS in the evaluation of comorbidities in MM patients with different scores, but its relationship to treatment responses was not significant contrary to other indices. While this small patient group gave us hope regarding the use of FCI in practice, multi-center studies are still required.

Munshi NC, Jagannath S (2013) Plasma cell neoplasms. In: Hoffman R, Benz EJ, Silberstein L, Heslop H, Weitz J, Anastasi J (eds) Hematology, basic principles and practice, 6th edn. Saunders, Philadelphia, pp 1303–1337

Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M et al (2012) Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 12(6):423–432CrossRefPubMed

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMed

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919CrossRefPubMedPubMedCentral

Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R et al (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1(9):e35CrossRefPubMedPubMedCentral

Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT et al (2012) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 95(1):64–70CrossRefPubMed

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420CrossRefPubMed

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al (2013) Mayo clinic. management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc Mayo Clin 88(4):360–376CrossRefPubMed

10.

Durie BG, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55(3):364–372PubMed

11.

Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519–4529CrossRefPubMed

12.

Wang R, Gross CP, Halene S, Ma X (2009) Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33(12):1594–1598CrossRefPubMedPubMedCentral

13.

Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090–1098CrossRefPubMed

14.

Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R et al (2013) Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 13(5):541–551CrossRefPubMed

15.

Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7–8):387–404CrossRefPubMed

16.

Kleber M, Ihorst G, Udi J, Koch B, Wasch R, Engelhardt M (2012) Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk 12(1):38–48CrossRefPubMed

Title: Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population
Publication date: 01-12-2016
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 4/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-015-0618-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Proliferation and Angiogenesis Using Immunohistochemistry in Prognosticating Multiple Myeloma

Prevalence and Prognostic Impact of CEBPA Gene Mutation (Simplified Assay Technique) in Egyptian Acute Myeloid Leukemia Patients with Normal Cytogenetics

Evaluation of Magnetized-Erythrocyte Group Antigens to Detect ABO Antibodies

Clinical Significance of Rare Maternal Anti Jka Antibody

Rhabdomyolysis After Allogeneic Hematopoietic Stem Cell Transplantation

Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed

Keynote webinar | Spotlight on antibody–drug conjugates in cancer